Lead Product(s) : CTX-101
Therapeutic Area : Dermatology
Study Phase : Phase III
Sponsor : Ferndale Laboratories
Deal Size : Inapplicable
Deal Type : Inapplicable
Crescita Reports Topline Results from Two Pivotal Clinical Studies
Details : Both studies of CTX-101 met the primary endpoint for psoriasis, CTX-101 is a topical formulation utilizing a corticosteroid in combination with our patented MMPE technology
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
November 02, 2020
Lead Product(s) : CTX-101
Therapeutic Area : Dermatology
Highest Development Status : Phase III
Sponsor : Ferndale Laboratories
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : IDP-126
Therapeutic Area : Dermatology
Study Phase : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Clinical Study Comparing the Efficacy and Safety of IDP-126 Gel in the Treatment of Acne Vulgaris
Details : Undisclosed
Product Name : Undisclosed
Product Type : Antibiotic
Upfront Cash : Inapplicable
January 02, 2020
Lead Product(s) : IDP-126
Therapeutic Area : Dermatology
Highest Development Status : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : IDP-126
Therapeutic Area : Dermatology
Study Phase : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Clinical Study Comparing the Efficacy and Safety of IDP-126 Gel in the Treatment of Acne Vulgaris
Details : Undisclosed
Product Name : Undisclosed
Product Type : Antibiotic
Upfront Cash : Inapplicable
January 02, 2020
Lead Product(s) : IDP-126
Therapeutic Area : Dermatology
Highest Development Status : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : IDP-120
Therapeutic Area : Dermatology
Study Phase : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Undisclosed
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Inapplicable
September 10, 2018
Lead Product(s) : IDP-120
Therapeutic Area : Dermatology
Highest Development Status : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : IDP-120
Therapeutic Area : Dermatology
Study Phase : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Undisclosed
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Inapplicable
September 10, 2018
Lead Product(s) : IDP-120
Therapeutic Area : Dermatology
Highest Development Status : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Tazarotene
Therapeutic Area : Dermatology
Study Phase : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
May 30, 2017
Lead Product(s) : Tazarotene
Therapeutic Area : Dermatology
Highest Development Status : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Tazarotene
Therapeutic Area : Dermatology
Study Phase : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
May 30, 2017
Lead Product(s) : Tazarotene
Therapeutic Area : Dermatology
Highest Development Status : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : IDP-124
Therapeutic Area : Dermatology
Study Phase : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Undisclosed
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Inapplicable
February 23, 2017
Lead Product(s) : IDP-124
Therapeutic Area : Dermatology
Highest Development Status : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : IDP-124
Therapeutic Area : Dermatology
Study Phase : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Undisclosed
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Inapplicable
December 23, 2016
Lead Product(s) : IDP-124
Therapeutic Area : Dermatology
Highest Development Status : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : IDP 121
Therapeutic Area : Dermatology
Study Phase : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Efficacy and Safety of IDP-121 and IDP-121 Vehicle Lotion in the Treatment of Acne Vulgaris
Details : Undisclosed
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Inapplicable
November 16, 2016
Lead Product(s) : IDP 121
Therapeutic Area : Dermatology
Highest Development Status : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable